Table 3.

Results of survival analyses in different grous

NSGO-EC-9501/EORTC-55991 (RT n=191, RT-CT n=187)
End-point	Events					HR	95% CI	P	5-yr probability of survival
	RT	%	RT-CT	%	Total				RT	RT-CT
PFS	50	26	35	19	85	0.64	0.41-0.99	0.04	0.72	0.79
OS	40	21	28	15	68	0.66	0.40-1.08	0.10	0.76	0.83
CSS	34	18	19	10	53	0.51	0.28-0.90	0.02	0.79	0.88
MaNGO ILIADE III (RT n=76, RT-CT n=80)
PFS	26	34	18	23	44	0.61	0.33-1.12	0.10	0.61	0.74
OS	17	22	14	18	31	0.74	0.36-1.52	0.41	0.73	0.78
CSS	15	20	11	14	26	0.65	0.30-1.44	0.29	0.76	0.82
POOLED NSGO-EC-9501/EORTC-55991+MaNGO ILIADE III (RT n=267, RT-CT n=267)
PFS	76	28	53	20	129	0.63	0.44-0.89	0.009	0.69	0.78
OS	57	21	42	16	99	0.69	0.46-1.03	0.07	0.75	0.82
CSS	49	18	30	11	79	0.55	0.35-0.88	0.01	0.78	0.87
NSGO-EC-9501/EORTC-55991 endometrioid carcinoma (RT n=115, RT-CT n=120)
PFS	29	25	19	16	48	0.50	0.27-0.95	0.03	0.73	0.83
OS	25	22	15	13	40	0.55	0.28-1.09	0.08	0.75	0.86
CSS	22	19	11	9	33	0.42	0.19-0.93	0.03	0.76	0.92
NSGO-EC-9501/EORTC-55991 serous and clear cell carcinoma (RT n=76, RT-CT n=64)
PFS	21	28	16	25	37	0.83	0.42-1.64	0.59	0.71	0.72
OS	15	20	13	20	28	0.94	0.42-2.08	0.88	0.78	0.77
CSS	12	16	8	13	20	0.71	0.26-1.90	0.49	0.82	0.85
POOLED NSGO-EC-9501/EORTC-55991+MaNGO ILIADE III endometrioid carcinoma (RT n=187, RT-CT n=197)
PFS	54	29	35	18	89	0.53	0.34-0.83	0.005	0.69	0.80
OS	41	22	27	14	68	0.60	0.36-1.00	0.05	0.74	0.84
CSS	36	19	21	11	57	0.51	0.29-0.91	0.02	0.77	0.87

Abbreviations: CI: confidence interval, CSS cancer-specific survival, HR: hazard ratio, OS: overall survival, PFS: progression-free survival, RT: radiotherapy, RT-CT: sequential radiotherapy and chemotherapy .